Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02457494
Other study ID # Al424-986
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 2015
Est. completion date March 2018

Study information

Verified date July 2022
Source Association pour le Developpement d'Investigations et de Thérapeutiques en Néphrologie
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to define the cause of renal stones and the risk pattern for recurrence of renal stones episodes (any kind of stones) in HIV1 patients.


Description:

This study aims at defining the cause of renal stones and the risk pattern for recurrence of renal stones episodes (any kind of stones) in HIV1 patients. Primary Objective : - Finding the cause of renal stone in HIV patients defined as stone composition if stone is available or more probable pathophysiological mechanism - Risk profile for stone recurrences estimated on risk indices in HIV1 patients Secondary Objective(s) - Identify prevalence of recurrences and describe co-morbidities associated with stone disease - Describe urological management for renal stones in HIV patients - Describe the causes of drug induced renal stones


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date March 2018
Est. primary completion date October 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult male or female HIV1 infected patients willing to participate in the study - Having experienced a renal stone episode within the past six months or living with a renal stone - Able to understand the protocol - Giving oral consent Exclusion Criteria: - CT scan impossible - Follow up impossible over 1 year

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Corinne Isnard Bagnis Paris

Sponsors (1)

Lead Sponsor Collaborator
Corinne Isnard Bagnis

Country where clinical trial is conducted

France, 

References & Publications (4)

Abgrall S, Rachas A, Tourret J, Isnard-Bagnis C, Billaud E, Tattevin P, Costagliola D, Guiguet M, Durieux P; French Hospital Database on HIV. A multifaceted intervention designed to improve medical management of moderate to advanced chronic kidney disease — View Citation

Bigé N, Lanternier F, Viard JP, Kamgang P, Daugas E, Elie C, Jidar K, Walker-Combrouze F, Peraldi MN, Isnard-Bagnis C, Servais A, Lortholary O, Noël LH, Bollée G. Presentation of HIV-associated nephropathy and outcome in HAART-treated patients. Nephrol Di — View Citation

Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol. 2013 Oct;24(10):1519-27. doi: 10.1681/ASN.2012080857. Epub 2013 Sep 19. Review. — View Citation

Tourret J, Tostivint I, Deray G, Isnard-Bagnis C. [Kidney diseases in HIV-infected patients]. Nephrol Ther. 2009 Nov;5(6):576-91. doi: 10.1016/j.nephro.2009.02.007. Epub 2009 Apr 16. French. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Qualitative assessment of the cause of the renal stone Qualitative assessment of the cause of the renal stone based on different biological and clinical parameters (biochemical analysis of urines, cristalluria, low dose renal CT, patient history, family history…) at 6 months
Primary Risk profile for recurrence of renal stone Risk profile for recurrence of renal stone estimated based on plasma and urinary parameters, nutritional profile and drug exposure at 12 months
Secondary Follow up outcome of HIV patients over one year to identify prevalence of recurrences and describe co-morbidities associated with stone disease up to 12 months
Secondary Urological management for renal stones in HIV patients up to 12 months
Secondary Causes of drug induced renal stones up to 12 months
Secondary Number of stone recurrences at 6 months
Secondary Number of stone recurrences at 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT06162897 - Case Management Dyad N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT02528773 - Efficacy of ART to Interrupt HIV Transmission Networks
Active, not recruiting NCT05454839 - Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
Recruiting NCT05322629 - Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women N/A
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Active, not recruiting NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04519970 - Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) N/A
Completed NCT04124536 - Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women N/A
Recruiting NCT05599581 - Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT02758093 - Speed of Processing Training in Adults With HIV N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2